Novo Nordisk a step closer to marketing Levemir  

2004.03.01
The EU Committee for Proprietary Medicinal Products (CPMP) has recommended marketing authorisation for Novo Nordisk's insulin drug

Healthcare company Novo Nordisk has announced that the EU Committee for Proprietary Medicinal Products (CPMP) has recommended marketing authorisation for Levemir, a long-acting insulin analogue for the treatment of diabetes. Novo Nordisk therefore expects the EU Commission to grant marketing authorisation in the near future so that Levemir can be launched in key European markets in H2 of 2004.

 

Levemir provides more consistent day-to-day control of blood glucose levels compared to conventional insulin preparations. When Levemir is launched, Novo will be the only manufacturer which has insulin analogues covering the full spectrum – fast-acting, slow-acting and mixed.

 

Novo Nordisk is a world leader in diabetes care. The company has the broadest product portfolio in the industry, including advanced products in the area of insulin delivery systems. Novo Nordisk employs approximately 18,800 people in 60 countries and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. The news is reported by national newspaper Jyllands-Posten and on Novo Nordisk's website.

 

Link > Novo Nordisk

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×